Evidence map›Paper›PMID 29511947›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985-2004).

R Clèries, A Ameijide, M Buxó, J M Martínez, R Marcos-Gragera, M-L Vilardell, M Carulla, Y Yasui, M Vilardell, J A Espinàs and 3 more

Abstract read
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

R ClèriesPla Director d'Oncologia (GENCAT), IDIBELL, Hospital Duran i Reynals, Gran Via 199-203 1ª planta, L'Hospitalet de Llobregat, 08908, Barcelona, Spain. r.cleries@iconcologia.net.ORCID http://orcid.org/0000-0002-3637-4747
A AmeijideRegistre de Càncer de Tarragona, Fundació Lliga per a la Investigació i Prevenció del Càncer (FUNCA)-IISPV, Reus, Tarragona, Spain.
M BuxóInstitut d'Investigació Biomèdica de Girona, IDIBGI, C/Dr.Castany s/n, Edifici M2, Parc Hospitalari Martí i Julià, 17190, Salt, Spain.
J M MartínezMC MUTUAL, Departamento de Investigación y Análisis de Prestaciones, C/Provenza, 321, 08037, Barcelona, Spain.
R Marcos-GrageraUnitat d'Epidemiologia i Registre del Càncer de Girona (UERGG), Institut d'Investigació Biomèdica Girona Josep Trueta (IDIBGI), Girona, Spain.
M-L VilardellUnitat d'Epidemiologia i Registre del Càncer de Girona (UERGG), Institut d'Investigació Biomèdica Girona Josep Trueta (IDIBGI), Girona, Spain.
M CarullaRegistre de Càncer de Tarragona, Fundació Lliga per a la Investigació i Prevenció del Càncer (FUNCA)-IISPV, Reus, Tarragona, Spain.
Y YasuiDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
M VilardellSección de Estadística del Departamento de Genética, Microbiología y Estadística de la Facultad de Biología, Universidad de Barcelona, 08028, Barcelona, Spain.
J A EspinàsPla Director d'Oncologia (GENCAT), IDIBELL, Hospital Duran i Reynals, Gran Via 199-203 1ª planta, L'Hospitalet de Llobregat, 08908, Barcelona, Spain.
J M BorràsPla Director d'Oncologia (GENCAT), IDIBELL, Hospital Duran i Reynals, Gran Via 199-203 1ª planta, L'Hospitalet de Llobregat, 08908, Barcelona, Spain.
J GalceranRegistre de Càncer de Tarragona, Fundació Lliga per a la Investigació i Prevenció del Càncer (FUNCA)-IISPV, Reus, Tarragona, Spain.
À IzquierdoUnitat d'Epidemiologia i Registre del Càncer de Girona (UERGG), Institut d'Investigació Biomèdica Girona Josep Trueta (IDIBGI), Girona, Spain.

Funding

Agència d'Avaluació d'Universitats i Recerca-GENCAT 2014SGR0635Instituto de Salud Carlos III PI14/01041
6 · The paper itself

Abstract

backgroundWe provide population-based long-term survival indicators of breast cancer patients by quantifying the observed survival, and the probabilities of death due to breast cancer and to other causes by age and tumor stage at diagnosis.

methodsWe included a total of 10,195 female patients diagnosed before 85 years with invasive primary breast cancer in Girona and Tarragona during the periods 1985-1994 and 1995-2004 and followed-up until December 31st 2014. The survival indicators were estimated at 5, 10, 15 and 20 years of follow-up comparing diagnostic periods.

resultsComparing diagnostic periods: I) the probability of death due to other causes did not change; II) the 20-year survival for women diagnosed ≤ 49 years increased 13% (1995-2004 = 68%; 1985-1994:55%), whereas their probability of death due to breast cancer decreased at the same pace (1995-2004 = 29%; 1985-1994 = 42%); III) at 10 years of follow-up, decreases in the probabilities of death due to breast cancer across age groups switched from 11 to 17% resulting in a risk of death reduction of 19% after adjusting by stage. During 1995-2004, the stage-specific 10-year probabilities of death due to breast cancer switched from: 3-6% in stage I, 18-20% in stage II, 34-46% in stage III and surpassed 70% in stage IV beyond 5 years after diagnosis.

conclusionsIn our study, women diagnosed with breast cancer had higher long-term probability to die from breast cancer than from other causes. The improvements in treatment and the lead-time bias in detecting cancer in an early stage resulted in a reduction of 19% in the risk of death between diagnostic periods.

Indexed as

AdolescentAdultAgedAged, 80 and overBreast NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingRegistriesSpainYoung AdultAgeBreast cancerProbability of deathStageSurvival

Identifiers

PMID29511947
PMCPMC6153860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.